NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Bolden Therapeutics

Bolden Therapeutics

Private
Providence, Rhode IslandHealthcare & Life Scienceshttps://www.boldentherapeutics.com/

Last Round

Pre Seed

Jan 17, 2024

Total Funding Raised

$2.9M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Bolden Therapeutics is a biotechnology company that develops first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

antisense oligonucleotideASOneurogenesisCNS therapeuticsAlzheimer's diseaseRNA therapeuticsneurodegenerative diseaseexon-skippingpreclinical biotechdrug discoveryneuroregenerationneural stem cellsdrug licensingischemic strokeSBIR grant

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bolden Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Bolden Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Bolden Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedJan 17, 2024
GrantSep 16, 2022
GrantJun 29, 2022
GrantSep 27, 2021

Key People

Founding team and executive leadership

Johnny Page

Co-Founder And CEO

Founding Team

Bolden Therapeutics Investors

Notable investors and investment history

Bolden Therapeutics investors
InvestorRounds
Resolute Venture PartnersPre Seed
NIH RADxGrant
National Institute on AgingGrant
LifeSpan Vision VenturesPre Seed
Slater Technology FundPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 135% MoM, reaching 836.

  • Mar 3, 2026

    Monthly visitors grew 209% MoM, reaching 1.2K.

Bolden Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Bolden Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Bolden Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersProvidence, Rhode Island
Employee Range3
Year Founded2019
Last FundingJan 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.